E
3.22
-0.37 (-10.31%)
| Previous Close | 3.59 |
| Open | 3.53 |
| Volume | 844,243 |
| Avg. Volume (3M) | 471,546 |
| Market Cap | 72,975,184 |
| Price / Sales | 1.15 |
| Price / Book | 4.51 |
| 52 Weeks Range | |
| Earnings Date | 10 Mar 2026 |
| Profit Margin | -27.34% |
| Operating Margin (TTM) | -21.71% |
| Diluted EPS (TTM) | -0.840 |
| Quarterly Revenue Growth (YOY) | 7.50% |
| Total Debt/Equity (MRQ) | 367.92% |
| Current Ratio (MRQ) | 2.32 |
| Operating Cash Flow (TTM) | -14.91 M |
| Levered Free Cash Flow (TTM) | -10.11 M |
| Return on Assets (TTM) | -19.21% |
| Return on Equity (TTM) | -117.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Exagen Inc. | Bearish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 1.30 |
|
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 19.82% |
| % Held by Institutions | 45.44% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (BTIG, 210.56%) | Buy |
| 10.00 (TD Cowen, 210.56%) | Buy | |
| Median | 10.00 (210.56%) | |
| Low | 8.00 (B. Riley Securities, 148.45%) | Buy |
| Average | 9.33 (189.75%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 3.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 24 Feb 2026 | 10.00 (210.56%) | Buy | 3.69 |
| BTIG | 17 Feb 2026 | 10.00 (210.56%) | Buy | 3.31 |
| B. Riley Securities | 30 Jan 2026 | 8.00 (148.45%) | Buy | 3.68 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ABALLI JOHN | - | 3.69 | -11,430 | -42,177 |
| BLACK JEFFREY G. | - | 3.69 | -1,584 | -5,845 |
| Aggregate Net Quantity | -13,014 | |||
| Aggregate Net Value ($) | -48,022 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 3.69 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BLACK JEFFREY G. | Officer | 24 Feb 2026 | Sell (-) | 1,584 | 3.69 | 5,845 |
| ABALLI JOHN | Officer | 24 Feb 2026 | Sell (-) | 11,430 | 3.69 | 42,177 |
| Date | Type | Details |
|---|---|---|
| 11 Jan 2026 | Announcement | Exagen Inc. Announces Select Preliminary 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |